Ask AI
ProCE Banner Activity

Mitigating Recurrence Risk: A Multisite QI Initiative to Improve Clinical Outcomes and Management in Patients With High-Risk HR+/HER2- EBC

Slideset

Downloadable slides on the results from a multisite quality improvement initiative in 5 cancer centers in 4 states in the US, with a focus on the management of patients with high-risk HR-positive/HER2-negative early breast cancer.

Released: April 24, 2026

Share

Provided by

Provided by Clinical Care Options, LLC, in partnership with Q Synthesis and The American Society of Breast Surgeons Foundation

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

Q Synthesis LLC

ProCE Banner

The American Society of Breast Surgeons Foundation

ProCE Banner

Target Audience

Oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals who care for patients with HR-positive/HER2-negative EBC within 3 community cancer centers and extended to a similar cohort of healthcare professionals across the United States.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize factors used to assess risk of recurrence in patients with HR+/HER2- EBC

  • Identify patients with high-risk HR+/HER2- EBC

  • Communicate assessment of risk and associated clinical and therapeutic implications to patients

  • Select guideline recommended adjuvant therapy for patients with HR+/HER2- EBC considering the patient’s risk of recurrence